2022 Archives - ISA Therapeutics BV

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

30 Nov 2022

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC).Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron.Top line interim results anticipated in third quarter of 2023.

Oegstgeest, 30 November 2022 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to announce that it has completed enrolment in its Phase 2 clinical trial named OpcemISA.

The OpcemISA trial has enrolled 194 patients and is a large randomized, double blind,

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

08 Nov 2022

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs).SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally.Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and safety when used as an intradermal therapeutic vaccine.

Oegstgeest, The Netherlands, 08 November 2022 – ISA is delighted to announce publication by Leiden University Medical Center (LUMC) of a phase 1 clinical study using ISA’s proprietary Amplivant® adjuvant and Synthetic Long Peptide (SLP®) therapeutic vaccine technology. The study

Professor Melief to receive 2022 SITC Pedro J. Romero Award

08 Sep 2022

The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting

Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (JITC) – the official journal of the SITC. The award will be presented at the SITC’s 37th

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

15 Jul 2022

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy

Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.

SITC is a professional society of scientists, clinicians, government representatives, and industry leaders

ISA to Present at Business Conferences in May 2022

27 Apr 2022

Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via info@isa-pharma.com.

LSX World Leaders Congress

Date: 10-11 May 2022, London, UK

Panel Presentation by: Anton Mat, Director Business Development, ISA Pharmaceuticals

Title: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making

Date & Time: Tuesday, 10 May 2022, 14.30pm BST

Bio€quity Europe

Date: 16-18 May 2022, Milan, Italy

Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals

Date & Time:

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

14 Apr 2022

AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 foldModi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer

Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant technology has started. The trial, run by partner Scancell Holdings plc (AIM: SCLP, “Scancell”) is a multicentre clinical trial, testing the Moditope® vaccine Modi1. This first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal

Long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

01 Mar 2022

Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1)Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 monthsImproved tumour infiltration by immune cells predicted response to therapy

Oegstgeest, March 1, 2022 – ISA today announces the publication of extension data from a key study using lead product ISA101b in the Journal of ImmunoTherapy of Cancer. The study, ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response, is performed by Guimaraes Sousa, Michael Curran, Bonnie Glisson et al. in

ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022

17 Feb 2022

Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals will be attending the following in person scientific and business conferences from February through to April 2022 (subject to travel restrictions), in addition to virtual conferences.

BioCapital Europe

Date: 10 March 2022, Amsterdam

American Association for Cancer Research (AACR) annual meeting

Date: 8-13 April 2022, New Orleans

2nd Chronic HBV drug development

Date: 25-27 April 2022, Boston

If you would like to meet with the ISA Pharmaceutical team at any of the above events, please contact us!